Katoh N, Kataoka Y, Saeki H, et al. - In Japanese individuals with moderate-to-severe atopic dermatitis (AD), researchers tested the safety and effectiveness of dupilumab, a human monoclonal antibody. Compared with the overall study population, baseline disease severity was numerically higher in the Japanese cohort. According to findings, dupilumab was related to an increased incidence of injection site reactions and conjunctivitis vs placebo. Dupilumab has been linked to rapid reductions in thymus and activation-regulated chemokine and gradual IgE reductions. In Japanese adult patients with moderate-to-severe AD, dupilumab alone or with topical corticosteroids improved signs and symptoms of AD, had an acceptable safety profile, and suppressed biomarkers of type 2 inflammation vs placebo.